Zhenya Lindgardt Sells 20,139 Shares of Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc. (NASDAQ:SERA) CEO Zhenya Lindgardt sold 20,139 shares of the company’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $2.00, for a total value of $40,278.00. Following the completion of the sale, the chief executive officer directly owned 844,870 shares in the company, valued at $1,689,740. This trade represents a 2.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Sera Prognostics Stock Down 0.5%

Shares of Sera Prognostics stock traded down $0.01 on Wednesday, hitting $2.00. The company’s stock had a trading volume of 8,250 shares, compared to its average volume of 49,384. The company has a market capitalization of $78.90 million, a P/E ratio of -2.99 and a beta of 0.98. Sera Prognostics, Inc. has a 52-week low of $1.56 and a 52-week high of $3.95. The firm has a fifty day moving average price of $2.05 and a 200-day moving average price of $2.02.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.03). Sera Prognostics had a negative return on equity of 46.71% and a negative net margin of 47,475.72%.The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.07 million. As a group, analysts expect that Sera Prognostics, Inc. will post -0.62 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SERA. Qube Research & Technologies Ltd purchased a new position in Sera Prognostics during the second quarter worth about $92,000. Captrust Financial Advisors increased its stake in shares of Sera Prognostics by 20.0% during the 2nd quarter. Captrust Financial Advisors now owns 602,277 shares of the company’s stock valued at $1,668,000 after acquiring an additional 100,366 shares during the last quarter. Corient Private Wealth LLC increased its stake in shares of Sera Prognostics by 73.9% during the 2nd quarter. Corient Private Wealth LLC now owns 100,000 shares of the company’s stock valued at $277,000 after acquiring an additional 42,500 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sera Prognostics by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,217,190 shares of the company’s stock worth $3,725,000 after acquiring an additional 54,008 shares during the period. Finally, Squarepoint Ops LLC boosted its position in shares of Sera Prognostics by 8.9% in the third quarter. Squarepoint Ops LLC now owns 93,063 shares of the company’s stock worth $285,000 after acquiring an additional 7,643 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have commented on SERA. Craig Hallum began coverage on Sera Prognostics in a report on Thursday, June 4th. They set a “buy” rating and a $6.00 target price on the stock. Weiss Ratings cut Sera Prognostics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Sera Prognostics presently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.